{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:59:21Z","timestamp":1783468761639,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:00:00Z","timestamp":1537142400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00415-018-9056-8","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T02:27:07Z","timestamp":1537151227000},"page":"2773-2782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Generalization after ocular onset in myasthenia gravis: a case series in Germany"],"prefix":"10.1007","volume":"265","author":[{"given":"Feng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Swierzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3940-4630","authenticated-orcid":false,"given":"Jens-C.","family":"R\u00fcckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,17]]},"reference":[{"key":"9056_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S (2016) Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12:259\u2013268","journal-title":"Nat Rev Neurol"},{"key":"9056_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036","journal-title":"Lancet Neurol"},{"key":"9056_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/WCO.0b013e328364c079","volume":"26","author":"L Querol","year":"2013","unstructured":"Querol L, Illa I (2013) Myasthenia gravis and the neuromuscular junction. Curr Opin Neurol 26:459\u2013465","journal-title":"Curr Opin Neurol"},{"key":"9056_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10:46","journal-title":"BMC Neurol"},{"key":"9056_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/ana.410140504","volume":"14","author":"CT Bever Jr","year":"1983","unstructured":"Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP (1983) Prognosis of ocular myasthenia. Ann Neurol 14:516\u2013519","journal-title":"Ann Neurol"},{"key":"9056_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0039-6257(94)90194-5","volume":"39","author":"DA Weinberg","year":"1994","unstructured":"Weinberg DA, Lesser RL, Vollmer TL (1994) Ocular myasthenia: a protean disorder. Surv Ophthalmol 39:169\u2013210","journal-title":"Surv Ophthalmol"},{"key":"9056_CR7","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/S0161-6420(99)00709-5","volume":"106","author":"KC Golnik","year":"1999","unstructured":"Golnik KC, Pena R, Lee AG, Eggenberger ER (1999) An ice test for the diagnosis of myasthenia gravis. Ophthalmology 106:1282\u20131286","journal-title":"Ophthalmology"},{"key":"9056_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ncl.2016.08.008","volume":"35","author":"SV Smith","year":"2017","unstructured":"Smith SV, Lee AG (2017) Update on ocular myasthenia gravis. Neurol Clin 35:115\u2013123","journal-title":"Neurol Clin"},{"key":"9056_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11940-011-0151-8","volume":"14","author":"SR Haines","year":"2012","unstructured":"Haines SR, Thurtell MJ (2012) Treatment of ocular myasthenia gravis. Curr Treat Options Neurol 14:103\u2013112","journal-title":"Curr Treat Options Neurol"},{"key":"9056_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/ene.12359","volume":"21","author":"E Kerty","year":"2014","unstructured":"Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE (2014) EFNS\/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol 21:687\u2013693","journal-title":"Eur J Neurol"},{"key":"9056_CR11","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/archneur.57.5.752","volume":"57","author":"HJ Kaminski","year":"2000","unstructured":"Kaminski HJ, Daroff RB (2000) Treatment of ocular myasthenia: steroids only when compelled. Arch Neurol 57:752\u2013753","journal-title":"Arch Neurol"},{"key":"9056_CR12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","volume":"53","author":"MJ Kupersmith","year":"1996","unstructured":"Kupersmith MJ, Moster M, Bhuiyan S, Warren F, Weinberg H (1996) Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 53:802\u2013804","journal-title":"Arch Neurol"},{"key":"9056_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","volume":"23","author":"J Mee","year":"2003","unstructured":"Mee J, Paine M, Byrne E, King J, Reardon K, O\u2019Day J (2003) Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 23:251\u2013255","journal-title":"J Neuroophthalmol"},{"key":"9056_CR14","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.athoracsur.2011.08.001","volume":"92","author":"Z Liu","year":"2011","unstructured":"Liu Z, Feng H, Yeung SC, Zheng Z, Liu W, Ma J, Zhong FT, Luo H, Cheng C (2011) Extended transsternal thymectomy for the treatment of ocular myasthenia gravis. Ann Thorac Surg 92:1993\u20131999","journal-title":"Ann Thorac Surg"},{"key":"9056_CR15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jtcvs.2012.12.053","volume":"145","author":"TC Mineo","year":"2013","unstructured":"Mineo TC, Ambrogi V (2013) Outcomes after thymectomy in class I myasthenia gravis. J Thorac Cardiovasc Surg 145:1319\u20131324","journal-title":"J Thorac Cardiovasc Surg"},{"key":"9056_CR16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1067\/mtc.2001.116191","volume":"122","author":"PF Roberts","year":"2001","unstructured":"Roberts PF, Venuta F, Rendina E, De Giacomo T, Coloni GF, Follette DM, Richman DP, Benfield JR (2001) Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg 122:562\u2013568","journal-title":"J Thorac Cardiovasc Surg"},{"key":"9056_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D (2015) Myasthenia gravis: association of British Neurologists\u2019 management guidelines. Pract Neurol 15:199\u2013206","journal-title":"Pract Neurol"},{"key":"9056_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0022-5223(96)70264-7","volume":"112","author":"H Nakamura","year":"1996","unstructured":"Nakamura H, Taniguchi Y, Suzuki Y, Tanaka Y, Ishiguro K, Fukuda M, Hara H, Mori T (1996) Delayed remission after thymectomy for myasthenia gravis of the purely ocular type. J Thorac Cardiovasc Surg 112:371\u2013375","journal-title":"J Thorac Cardiovasc Surg"},{"key":"9056_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","volume":"273","author":"YH Hong","year":"2008","unstructured":"Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK, Park KS, Park KJ, Sung JJ, Sohn EH, Lee YB, Jeong D, Joo IS, Choi BO, Choi YC, Korean Research Group for Neuromuscular D (2008) Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci 273:10\u201314","journal-title":"J Neurol Sci"},{"key":"9056_CR20","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","volume":"122","author":"L Nagia","year":"2015","unstructured":"Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER (2015) Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology 122:1517\u20131521","journal-title":"Ophthalmology"},{"key":"9056_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2017.09.036","volume":"382","author":"ME Farrugia","year":"2017","unstructured":"Farrugia ME, Cleary M, Carmichael C (2017) A retrospective study of acetylcholine receptor antibody positive ocular myasthenia in the West of Scotland. J Neurol Sci 382:84\u201386","journal-title":"J Neurol Sci"},{"key":"9056_CR22","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.4103\/0366-6999.166032","volume":"128","author":"LL Wang","year":"2015","unstructured":"Wang LL, Zhang Y, He ML (2015) Clinical features and prognosis of ocular myasthenia gravis patients with different phenotypes. Chin Med J (Engl) 128:2682\u20132684","journal-title":"Chin Med J (Engl)"},{"key":"9056_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fneur.2018.00077","volume":"9","author":"X Huang","year":"2018","unstructured":"Huang X, Li Y, Feng H, Chen P, Liu W (2018) Clinical characteristics of juvenile myasthenia gravis in Southern China. Front Neurol 9:77","journal-title":"Front Neurol"},{"key":"9056_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mus.25983","volume":"57","author":"KY Teo","year":"2018","unstructured":"Teo KY, Tow SL, Haaland B, Gosavi TD, Jing-Liang L, Yew Long LO, Milea D (2018) Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle Nerve 57:756\u2013760","journal-title":"Muscle Nerve"},{"key":"9056_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","volume":"128","author":"M Mazzoli","year":"2018","unstructured":"Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, Galassi G (2018) Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci 128:15\u201324","journal-title":"Int J Neurosci"},{"key":"9056_CR26","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/mus.25971","volume":"57","author":"SK Kamarajah","year":"2018","unstructured":"Kamarajah SK, Sadalage G, Palmer J, Carley H, Maddison P, Sivaguru A (2018) Ocular presentation of myasthenia gravis: a natural history cohort. Muscle Nerve 57:622\u2013627","journal-title":"Muscle Nerve"},{"key":"9056_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000487132","volume":"79","author":"F Aguirre","year":"2018","unstructured":"Aguirre F, Villa AM (2018) Prognosis of ocular myasthenia gravis in an Argentinian population. Eur Neurol 79:113\u2013117","journal-title":"Eur Neurol"},{"key":"9056_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11910-013-0421-9","volume":"14","author":"SH Wong","year":"2014","unstructured":"Wong SH, Huda S, Vincent A, Plant GT (2014) Ocular myasthenia gravis: controversies and updates. Curr Neurol Neurosci 14:421","journal-title":"Curr Neurol Neurosci"},{"key":"9056_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jama.1953.02940230001001","volume":"153","author":"D Grob","year":"1953","unstructured":"Grob D (1953) Course and management of myasthenia gravis. J Am Med Assoc 153:529\u2013532","journal-title":"J Am Med Assoc"},{"key":"9056_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","volume":"62","author":"N Sommer","year":"1997","unstructured":"Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J (1997) Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62:156\u2013162","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9056_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"MJ Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P (2003) Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 60:243\u2013248","journal-title":"Arch Neurol"},{"key":"9056_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","volume":"217","author":"NT Monsul","year":"2004","unstructured":"Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM (2004) The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 217:131\u2013133","journal-title":"J Neurol Sci"},{"key":"9056_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/WNO.0000000000000350","volume":"36","author":"SH Wong","year":"2016","unstructured":"Wong SH, Petrie A, Plant GT (2016) Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification. J Neuroophthalmol 36:252\u2013258","journal-title":"J Neuroophthalmol"},{"key":"9056_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/mus.21555","volume":"41","author":"JA Allen","year":"2010","unstructured":"Allen JA, Scala S, Jones HR (2010) Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve 41:379\u2013384","journal-title":"Muscle Nerve"},{"key":"9056_CR35","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","volume":"256","author":"MJ Kupersmith","year":"2009","unstructured":"Kupersmith MJ (2009) Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 256:1314\u20131320","journal-title":"J Neurol"},{"key":"9056_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/CND.0b013e31821c5634","volume":"13","author":"MK Mittal","year":"2011","unstructured":"Mittal MK, Barohn RJ, Pasnoor M, McVey A, Herbelin L, Whittaker T, Dimachkie M (2011) Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response. J Clin Neuromuscul Dis 13:46\u201352","journal-title":"J Clin Neuromuscul Dis"},{"key":"9056_CR37","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/ene.12057","volume":"20","author":"H Zach","year":"2013","unstructured":"Zach H, Cetin H, Hilger E, Paul A, Wuschitz B, Jung R, Auff E, Zimprich F (2013) The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis. Eur J Neurol 20:708\u2013713","journal-title":"Eur J Neurol"},{"key":"9056_CR38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.24769","volume":"53","author":"M Benatar","year":"2016","unstructured":"Benatar M, McDermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ, Hehir M, Juel V, Katzberg H, Tawil R, Muscle Study G (2016) Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve 53:363\u2013369","journal-title":"Muscle Nerve"},{"key":"9056_CR39","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A (2008) IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis. Brain 131:1940\u20131952","journal-title":"Brain"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-9056-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9056-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9056-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T19:12:13Z","timestamp":1568661133000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-9056-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,17]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["9056"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-9056-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,17]]},"assertion":[{"value":"17 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no financial or other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This research was approved by Ethics Committee of Charite Universitaetsmedizin Berlin (Berlin, Germany).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"All patients gave their informed consent prior to their inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}